Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) insider Joanne Curley sold 1,545 shares of the business’s stock in a transaction on Wednesday, June 22nd. The stock was sold at an average price of $15.01, for a total value of $23,190.45. Following the sale, the insider now owns 23,688 shares in the company, valued at $355,556.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Joanne Curley also recently made the following trade(s):
- On Friday, June 17th, Joanne Curley sold 5,887 shares of Vera Therapeutics stock. The stock was sold at an average price of $15.04, for a total value of $88,540.48.
NASDAQ:VERA traded down $0.60 during trading hours on Thursday, reaching $13.62. 43,567 shares of the stock were exchanged, compared to its average volume of 100,045. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.04. The firm has a 50 day simple moving average of $16.75 and a 200-day simple moving average of $20.24. Vera Therapeutics, Inc. has a 52 week low of $12.28 and a 52 week high of $37.11. The stock has a market capitalization of $368.63 million and a P/E ratio of -6.22.
Several institutional investors have recently made changes to their positions in VERA. UBS Group AG acquired a new stake in shares of Vera Therapeutics during the 1st quarter worth approximately $47,000. American International Group Inc. increased its position in Vera Therapeutics by 29.2% in the 1st quarter. American International Group Inc. now owns 6,794 shares of the company’s stock valued at $160,000 after acquiring an additional 1,535 shares during the period. New York State Common Retirement Fund increased its position in Vera Therapeutics by 445.8% in the 4th quarter. New York State Common Retirement Fund now owns 6,549 shares of the company’s stock valued at $175,000 after acquiring an additional 5,349 shares during the period. MetLife Investment Management LLC acquired a new stake in Vera Therapeutics in the 1st quarter valued at approximately $209,000. Finally, Rhumbline Advisers acquired a new stake in Vera Therapeutics in the 1st quarter valued at approximately $244,000. Institutional investors and hedge funds own 78.57% of the company’s stock.
VERA has been the subject of several research analyst reports. Wedbush assumed coverage on Vera Therapeutics in a research note on Monday, April 18th. They set an “outperform” rating and a $32.00 price target for the company. HC Wainwright started coverage on Vera Therapeutics in a report on Monday, May 2nd. They issued a “buy” rating and a $35.00 price target for the company. Finally, Lifesci Capital reissued an “outperform” rating on shares of Vera Therapeutics in a report on Monday, March 28th.
Vera Therapeutics Company Profile (Get Rating)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
- Get a free copy of the StockNews.com research report on Vera Therapeutics (VERA)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.